Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc.
- Market cap
- $1.43B
Your view on KLRA
Overview
What the company does, where it operates, and who runs it.
About Kailera Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ronald C. Renaud Jr.
- Headquarters
- 180 Third Avenue, 4th Floor, Waltham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ronald C. Renaud Jr.
- Headquarters
- 180 Third Avenue, 4th Floor, Waltham, MA, US
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders.
The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Kailera Therapeutics, Inc.. Starting points for Kailera Therapeutics, Inc.: EPS -$2.69, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Kailera Therapeutics, Inc.. Trailing twelve-month EPS for Kailera Therapeutics, Inc. stands at -$2.69. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Targets, low to high
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.90 | −$0.84 | −$3.92 | −$3.86 |
| Lowest estimate | −$1.01 | −$0.84 | −$4.71 | −$4.55 |
| Highest estimate | −$0.80 | −$0.84 | −$3.13 | −$2.91 |
| Number of analysts | 4 | 1 | 4 | 5 |
| A year ago | — | −$3,650.001 | −$1.261 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Lowest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Highest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Number of analysts | 0 | 0 | 0 | 0 |
| A year ago | — | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Kailera Therapeutics, Inc.. Kailera Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ALTAltimmune, Inc. | Healthcare | Biotechnology | $258.8M | ||
| BIOABioAge Labs, Inc. | Healthcare | Biotechnology | $161.1M | ||
| BMEABiomea Fusion, Inc. | Healthcare | Biotechnology | $41.7M | ||
| GUTSFractyl Health, Inc. Common Stock | Healthcare | Biotechnology | $10.9M | ||
| MBXMBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $2.5B | ||
| MTVAMetaVia Inc. | Healthcare | Biotechnology | $6.8M | ||
| NAMSNewAmsterdam Pharma Company N.V. | Healthcare | Biotechnology | $2.2B | ||
| ORMPOramed Pharmaceuticals Inc. | Healthcare | Biotechnology | $155.2M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NXTCNextCure, Inc. | Healthcare | NASDAQ | $29.5M | ||
| NYMXFNymox Pharmaceutical Corporation | Healthcare | OTC | $4.8M | ||
| NYR.AXNyrada Inc. | Healthcare | ASX | — | ||
| OABIOmniAb, Inc. | Healthcare | NASDAQ | $679.7M | ||
| OABIWOmniAb, Inc. | Healthcare | NASDAQ | $733.7M | ||
| OBIOOrchestra BioMed Holdings, Inc. | Healthcare | NASDAQ | $517.9M | ||
| MDXGMiMedx Group, Inc. | Healthcare | NASDAQ | $445.1M | ||
| MEM.AXMemphasys Limited | Healthcare | ASX | — | ||
| MENSJyong Biotech Ltd. Ordinary Shares | Healthcare | NASDAQ | $110.2M | ||
| MEOBFMesoblast Limited | Healthcare | OTC | $2.1B | ||
| MESOMesoblast Limited | Healthcare | NASDAQ | $1.4B | ||
| MGNXMacroGenics, Inc. | Healthcare | NASDAQ | $125.3M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | $10.0B in assets | 0.15% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.02% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VBVanguard Small-Cap ETF | $76.9B in assets | 0.01% | |
| OZEMRoundhill Investments - GLP-1 & Weight Loss ETF | $57M in assets | 4.40% | |
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 1.02% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.03% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.02% | |
Largest holders first, then the funds most concentrated in KLRA.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Kailera Therapeutics, Inc., and how their positions are changing. At a $1.43B market value, institutional positions materially move Kailera Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Kailera Therapeutics, Inc. executives and directors. Shares of Kailera Therapeutics, Inc. have traded between $16.39 and $28.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Kailera Therapeutics, Inc.. Coverage tracks Kailera Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Kailera Therapeutics, Inc.